Videos

Long-term data on sipuleucel-T reveal significant survival benefits, emphasizing the importance of multiple lines of therapy in patient outcomes.

Sameena A. Rahman, MD, said she sees this development as a hopeful signal amid a challenging landscape for women’s health care.

Experts discuss the importance of early treatment with Provenge for prostate cancer, highlighting patient demographics and response variability.

Bradley McGregor, MD, contextualizes recent data on emerging treatment regimens in high-risk, BCG-naïve NMIBC.

Daneshmand also emphasized the evolving, highly collaborative role between urologists and medical oncologists as perioperative systemic regimens expand.

Identifying the Ideal Patient for Doublet versus triplet in mCSPC

Discover how safe spacer placement enhances prostate cancer treatment, improves patient outcomes, and minimizes side effects during radiation therapy.

Mills warns that poorly justified combination regimens complicate downstream management for urologists.

Explore the latest long-term data on abiraterone and enzalutamide, revealing survival benefits and safety insights for prostate cancer treatments.

Discover how rectal spacers enhance prostate radiotherapy outcomes by reducing side effects and improving treatment precision in cancer care.

Laura Bukavina, MD, MPH, MSc, recapped a debate at SUO 2025 on how to appropriately classify high-grade bladder tumors.

Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men.

Panelists discuss how closing real-world evidence gaps through inclusive research and advanced data integration will refine sequencing strategies and improve outcomes for patients with mCSPC.

The expert faculty review the phase 3 POTOMAC trial, presented at ESMO, which evaluated durvalumab combined with Bacillus Calmette–Guérin (BCG) in patients with high-risk, BCG-naïve non–muscle invasive bladder cancer (NMIBC).

Aleece Fosnight, MSPAS, PA-C, argues that incontinence must be understood as a common, treatable medical condition rather than a personal failure or an inevitable part of aging.

Panelists discuss how multidisciplinary collaboration and integration of RWE with NCCN guidelines strengthen ARPI adherence, sequencing, and continuity of care for patients with mCSPC.

The expert faculty review the pivotal phase 3 CREST trial, which evaluated subcutaneous sasanlimab in combination with Bacillus Calmette–Guérin (BCG) for BCG-naïve, high-risk non–muscle invasive bladder cancer (NMIBC).

Fed Ghali, MD, discusses the potential opportunity to de-escalate therapy in patients receiving perioperative EV/pembro.

Gal Wald, MD, highlights patient-reported outcomes from a phase 2 trial of intravesical gemcitabine plus BCG for patients with BCG-exposed high-grade NMIBC.

Explore the complexities of treating mCRPC with personalized immunotherapies, addressing comorbidities and patient response challenges.

Healthcare professionals discuss adapting treatment guidelines based on genomic testing, emphasizing early detection and personalized care for high-risk patients.

Another critical research need involves understanding the effects of exogenous testosterone.

Sameena A. Rahman, MD, said she anticipates that the regulatory stance may encourage more clinicians to adopt a layered therapeutic approach for patients with severe GSM.

Lin Lin, MD, highlights a phase 2 trial of neoadjuvant SAbR followed by surgery in patients with newly diagnosed renal cell carcinoma and caval tumor thrombus.

Eugene Pietzak, MD, highlights the background and design of the ongoing phase 3 GAIN trial, exploring the combination of gemcitabine and BCG in BCG-exposed NMIBC.

The primary end point is overall survival, with secondary end points including PSA response metrics, progression measures, PSA kinetics, and several ctDNA assessments to help identify which patients benefit most.

Arvin K. George, MD, discusses the unique design of the VAPOR 2 trial and the key findings from the first 110 patients enrolled.

Siamak Daneshmand, MD, emphasizes that, at present, optimal patient selection remains unclear because resistance mechanisms and predictive biomarkers are not yet well understood.

Explore the evolving landscape of prostate cancer treatments, focusing on efficacy, tolerability, and the nuances of various therapies.

Experts discuss the future of metastatic cancer treatment, focusing on risk stratification, personalized therapies, and the balance between intensification and de-escalation.